Status:
UNKNOWN
Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen
Lead Sponsor:
NanoCarrier Co., Ltd.
Collaborating Sponsors:
Orient Europharma Co., Ltd.
Conditions:
SCCHN
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
In Phase IIa, dose-escalation study to determine the optimum tolerated dose and a recommended Phase IIb (RPIIb) dose in combination with pembrolizumab in subjects with recurrent or metastatic squamous...
Eligibility Criteria
Inclusion
- Be willing and able to provide written informed consent for the trial.
- Males or females aged ≥18 years at screening.
- Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
- Have histologically- or cytologically-confirmed HNSCC.
- Have recurrent disease not amenable to curative treatment with local or systemic therapy, or metastatic (disseminated) HNSCC of the oral cavity, oropharynx, hypopharynx, or larynx that is considered incurable by local therapies.
- Having prior platinum failure.
Exclusion
- Subjects with carcinoma of the nasopharynx, squamous cell carcinoma of unknown primary origination, squamous cell carcinoma that originates from the skin and salivary gland or paranasal sinus, nonsquamous histologies.
- Have disease that is suitable for locoregional treatment administered with curative intent or refuses curative intent.
- Have no more than 15% body weight loss due to the underlying condition in the last 3 months from signing of informed consent in Part 1 of the study and from randomization in to Part 2.
- Are currently participating in or have participated in a study of an investigational agent or are using an investigational device within 4 weeks prior to the first dose of trial treatment.
- Were previously treated with 3 or more lines of systemic therapies administered for recurrent and/or metastatic disease.
Key Trial Info
Start Date :
July 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 30 2022
Estimated Enrollment :
136 Patients enrolled
Trial Details
Trial ID
NCT03771820
Start Date
July 1 2019
End Date
April 30 2022
Last Update
March 17 2021
Active Locations (24)
Enter a location and click search to find clinical trials sorted by distance.
1
0603
Osijek, Croatia
2
0601
Zagreb, Croatia
3
0602
Zagreb, Croatia
4
0701
Brno, Czechia